ARCUTIS BIOTHERAPEUTICS INC. - COMMON STOCK

Arcutis Appoints Interim Chief Financial Officer (CFO)

18 8月 2023 15:30:00 条件 Nasdaq GlobeNewswire

Arcutis and Huadong Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Greater China and Southeast Asia

10 8月 2023 07:16:31 条件 Nasdaq GlobeNewswire

Arcutis Announces Second Quarter 2023 Financial Results and Provides Business Update

08 8月 2023 15:02:00 条件 Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 8月 2023 15:00:00 条件 Nasdaq GlobeNewswire

Arcutis Announces ZORYVE® (Roflumilast) Cream 0.3% Has Been Included in a Preferred Position on National Formularies for CVS Caremark

17 7月 2023 07:00:01 条件 Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 7月 2023 15:00:00 条件 Nasdaq GlobeNewswire

Arcutis to Present at Upcoming Investor Conference

06 6月 2023 15:00:00 条件 Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 6月 2023 15:00:00 条件 Nasdaq GlobeNewswire

Arcutis Announces Leadership Transition

24 5月 2023 16:00:03 条件 Nasdaq GlobeNewswire

Arcutis Announces First Quarter 2023 Financial Results and Provides Business Update

09 5月 2023 15:02:00 条件 Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 5月 2023 15:00:00 条件 Nasdaq GlobeNewswire

Arcutis Completes Enrollment in INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5

02 5月 2023 07:00:01 条件 Nasdaq GlobeNewswire

Arcutis Announces Canadian Approval of ZORYVE™ (roflumilast) Cream 0.3% for Treatment of Plaque Psoriasis in Individuals 12 Years and Older

28 4月 2023 15:01:57 条件 Nasdaq GlobeNewswire

Arcutis to Report First Quarter Financial Results

25 4月 2023 15:00:00 条件 Nasdaq GlobeNewswire

Arcutis Announces FDA Acceptance of New Drug Application for Roflumilast Foam 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older

18 4月 2023 07:00:01 条件 Nasdaq GlobeNewswire

Arcutis to Present at Upcoming Investor Conference

12 4月 2023 15:45:00 条件 Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

07 4月 2023 15:00:00 条件 Nasdaq GlobeNewswire

Arcutis Announces New Coverage for ZORYVE® (Roflumilast) Cream 0.3% with National and Regional Health Plan Formularies, Bringing Total Commercial Covered Lives to Over 110 Million

05 4月 2023 07:00:00 条件 Nasdaq GlobeNewswire

Arcutis Presents Late-Breaking Data from the INTEGUMENT Phase 3 Trials in Atopic Dermatitis at American Academy of Dermatology Annual Meeting

18 3月 2023 06:00:00 条件 Nasdaq GlobeNewswire

Arcutis to Present New Topical Roflumilast Data Including Late Breaking Atopic Dermatitis Pivotal Trial Data During the American Academy of Dermatology (AAD) Annual Meeting

09 3月 2023 07:00:01 条件 Nasdaq GlobeNewswire